FDA approval
FDA approves daraxonrasib as RASONQUE for metastatic pancreatic adenocarcinoma
The approval marks a major status change for the compound long known as RMC-6236. Our update separates the approved finished medicine from research-use daraxonrasib material and links directly to FDA sources.
Read the update →